3 Penny Stocks With At Least $70M Market Cap

Over the last 7 days, the United States market has dropped by 1.5%, though it has seen an overall rise of 18% over the past year, with earnings expected to grow by 17% annually in the coming years. Penny stocks, while an outdated term, still hold relevance as they can offer a blend of affordability and growth potential when supported by strong financials. In this article, we will explore several penny stocks that stand out for their financial strength and potential for long-term success.

Underneath we present a selection of stocks filtered out by our screen.

AlTi Global (ALTI)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: AlTi Global, Inc. offers wealth and asset management services across several countries including France, Hong Kong, Italy, Portugal, Singapore, Switzerland, the United Kingdom, and the United States with a market cap of $624.76 million.

Operations: The company's revenue is primarily derived from its Wealth & Capital Solutions segment, which generated $276.62 million.

Market Cap: $624.76M

AlTi Global, Inc., with a market cap of US$624.76 million, is navigating its unprofitable status while maintaining a positive free cash flow and sufficient cash runway for over three years. Recent earnings show revenue growth to US$58.02 million in Q2 2026, though the company continues to incur net losses. Despite this, AlTi's short-term assets exceed short-term liabilities, providing some financial stability. The company's strategic moves include adding Patrick Keenan as CFO and being included in multiple Russell Growth Benchmarks, which may bolster its market visibility and investor confidence amidst ongoing challenges in profitability and board experience.

• Jump into the full analysis health report here for a deeper understanding of AlTi Global.
• Assess AlTi Global's future earnings estimates with our detailed growth reports.

CVRx (CVRX)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: CVRx, Inc. is a commercial-stage medical device company focused on developing, manufacturing, and commercializing neuromodulation solutions for cardiovascular diseases globally, with a market cap of $75.66 million.

Operations: The company generates revenue from its Medical Products segment, totaling $61.19 million.

Market Cap: $75.66M

CVRx, Inc., with a market cap of US$75.66 million, is navigating its unprofitable status while generating revenue from its medical products segment, totaling US$61.19 million. Despite recent leadership changes and activist investor pressure for a strategic sale to unlock value, CVRx maintains financial stability with short-term assets of US$89.5 million exceeding liabilities and more cash than debt. The company has a cash runway exceeding one year if current free cash flow trends persist but faces challenges in profitability and high share price volatility amidst industry competition and the evolving medical device landscape.

• Unlock comprehensive insights into our analysis of CVRx stock in this financial health report.
• Explore CVRx's analyst forecasts in our growth report.

OPKO Health (OPK)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: OPKO Health, Inc. is a healthcare company with operations in the United States, Ireland, Chile, Spain, Israel, Mexico, and other international markets; it has a market cap of approximately $1.10 billion.

Operations: The company's revenue is primarily derived from its Diagnostics segment, generating $313.07 million, and its Pharmaceutical segment, contributing $274.83 million.

Market Cap: $1.1B

OPKO Health, Inc. operates with a market cap of US$1.10 billion, generating significant revenue from its Diagnostics and Pharmaceutical segments. Despite being unprofitable with a negative return on equity of -6.16%, the company has managed to reduce its net loss significantly over the past year while maintaining stable short-term assets that exceed liabilities. Recent financing activities have provided non-dilutive capital through senior secured notes tied to royalty interests in mazdutide sales in China, enhancing liquidity without shareholder dilution. However, OPKO faces challenges with increased debt levels and earnings forecasted to decline by 13% annually over three years.

• Navigate through the intricacies of OPKO Health with our comprehensive balance sheet health report here.
• Review our growth performance report to gain insights into OPKO Health's future.

Taking Advantage

• Unlock more gems! Our US Penny Stocks screener has unearthed 311 more companies for you to explore.Click here to unveil our expertly curated list of 314 US Penny Stocks.
• Looking For Alternative Opportunities? The end of cancer? These 34 emerging AI stocks are developing tech that will allow early idenification of life changing disesaes like cancer and Alzheimer's.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com